Management of bone fragility in patients with rheumatoid arthritis in France: An analysis of a national health insurance claims database - 29/06/22
Highlights |
• | Patients with RA exposed to corticosteroids are at a high risk of fracture. |
• | Patients with rheumatoid arthritis (RA) have more bone fragility management than patients without RA. |
Abstract |
Objectives |
Rheumatoid arthritis (RA) is considered a major risk factor for fragility fractures. We examined the quality of management of bone fragility in RA patients in a real-life setting.
Methods |
We performed a longitudinal case-control retrospective study in a 1/97th random sample of French health care claims database from 2014 to 2016 to determine the extent of bone fragility management in patients with RA compared with non-RA matched controls.
Results |
Compared to their non-RA controls (n=4652), RA patients (n=1008; mean age: 61.1years; methotrexate: 69.7%; other conventional disease-modifying antirheumatic drugs (cDMARDs): 26.8%; biologic: 26.0%; corticosteroids: 36.9%) had more reimbursements for bone mineral density (BMD) measurements (21.6 vs. 9.2%; OR=2.7 [2.3; 3.3]; P<0.01) and for bisphosphonates (7.1 vs. 3.6%, OR=2.0 [1.5; 2.7]; P<0.05). In patients exposed to corticosteroids, RA patients underwent more BMD assessments than non-RA controls (28.0 vs. 18.8%; OR=1.7 [1.3; 2.2]; P<0.05). RA patients exposed to corticosteroids were more likely to sustain fracture than non-exposed RA patients (5.7 vs. 2.4%, P<0.01). In addition, only when comparing patients exposed to corticosteroids, was there statistical evidence of an association between RA and an increased fracture rate (6.2 vs. 3.5%, P<0.05).
Conclusion |
Patients with RA exposed to corticosteroids are at high risk of fracture. Patients with RA had more bone fragility management than controls.
El texto completo de este artículo está disponible en PDF.Keywords : Rheumatoid arthritis, Bone fragility, Fractures, Case-control study, French claims data (EGB)
Esquema
Vol 89 - N° 4
Artículo 105340- juillet 2022 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?